These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32413258)

  • 21. Normalizing Tumor Vessels To Increase the Enzyme-Induced Retention and Targeting of Gold Nanoparticle for Breast Cancer Imaging and Treatment.
    Xiao W; Ruan S; Yu W; Wang R; Hu C; Liu R; Gao H
    Mol Pharm; 2017 Oct; 14(10):3489-3498. PubMed ID: 28845990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles.
    Shashni B; Nishikawa Y; Nagasaki Y
    Biomaterials; 2021 Feb; 269():120645. PubMed ID: 33453633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models.
    Maione F; Molla F; Meda C; Latini R; Zentilin L; Giacca M; Seano G; Serini G; Bussolino F; Giraudo E
    J Clin Invest; 2009 Nov; 119(11):3356-72. PubMed ID: 19809158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet-camouflaged nanococktail: Simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cells and tumor vasculature dual-targeting strategy.
    Jing L; Qu H; Wu D; Zhu C; Yang Y; Jin X; Zheng J; Shi X; Yan X; Wang Y
    Theranostics; 2018; 8(10):2683-2695. PubMed ID: 29774068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gold nanoparticles and angiogenesis: molecular mechanisms and biomedical applications.
    Darweesh RS; Ayoub NM; Nazzal S
    Int J Nanomedicine; 2019; 14():7643-7663. PubMed ID: 31571869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PEGylated polyethylenimine-entrapped gold nanoparticles modified with folic acid for targeted tumor CT imaging.
    Zhou B; Yang J; Peng C; Zhu J; Tang Y; Zhu X; Shen M; Zhang G; Shi X
    Colloids Surf B Biointerfaces; 2016 Apr; 140():489-496. PubMed ID: 26812636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models.
    Casazza A; Fu X; Johansson I; Capparuccia L; Andersson F; Giustacchini A; Squadrito ML; Venneri MA; Mazzone M; Larsson E; Carmeliet P; De Palma M; Naldini L; Tamagnone L; Rolny C
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):741-9. PubMed ID: 21205984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diosmetin inhibits tumor development and block tumor angiogenesis in skin cancer.
    Choi J; Lee DH; Park SY; Seol JW
    Biomed Pharmacother; 2019 Sep; 117():109091. PubMed ID: 31228803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis.
    Guttmann-Raviv N; Shraga-Heled N; Varshavsky A; Guimaraes-Sternberg C; Kessler O; Neufeld G
    J Biol Chem; 2007 Sep; 282(36):26294-305. PubMed ID: 17569671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sema3A drastically suppresses tumor growth in oral cancer Xenograft model of mice.
    Huang C; Wang Y; Huang JH; Liu W
    BMC Pharmacol Toxicol; 2017 Jul; 18(1):55. PubMed ID: 28683823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.
    Hijaz M; Das S; Mert I; Gupta A; Al-Wahab Z; Tebbe C; Dar S; Chhina J; Giri S; Munkarah A; Seal S; Rattan R
    BMC Cancer; 2016 Mar; 16():220. PubMed ID: 26979107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smad2/Smad3 in endothelium is indispensable for vascular stability via S1PR1 and N-cadherin expressions.
    Itoh F; Itoh S; Adachi T; Ichikawa K; Matsumura Y; Takagi T; Festing M; Watanabe T; Weinstein M; Karlsson S; Kato M
    Blood; 2012 May; 119(22):5320-8. PubMed ID: 22498737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-Terminal Modification of the Tetrapeptide Arg-Leu-Tyr-Glu, a Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Antagonist, Improves Antitumor Activity by Increasing its Stability against Serum Peptidases.
    Yun JA; Kim J; Baek YY; Park W; Park M; Kim S; Kim T; Choi S; Jeoung D; Lee H; Won MH; Kim JY; Ha KS; Kwon YG; Kim YM
    Mol Pharmacol; 2019 Dec; 96(6):692-701. PubMed ID: 31594790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-RhoJ antibody functionalized Au@I nanoparticles as CT-guided tumor vessel-targeting radiosensitizers in patient-derived tumor xenograft model.
    Liu S; Li H; Xia L; Xu P; Ding Y; Huo D; Hu Y
    Biomaterials; 2017 Oct; 141():1-12. PubMed ID: 28666098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular mimicry formation is promoted by paracrine TGF-β and SDF1 of cancer-associated fibroblasts and inhibited by miR-101 in hepatocellular carcinoma.
    Yang J; Lu Y; Lin YY; Zheng ZY; Fang JH; He S; Zhuang SM
    Cancer Lett; 2016 Dec; 383(1):18-27. PubMed ID: 27693460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smart Nanotherapeutic Targeting of Tumor Vasculature.
    Li Z; Di C; Li S; Yang X; Nie G
    Acc Chem Res; 2019 Sep; 52(9):2703-2712. PubMed ID: 31433171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anterior gradient 2 as a supervisory marker for tumor vessel normalization induced by anti-angiogenic treatment.
    Pan F; Li W; Yang W; Yang XY; Liu S; Li X; Zhao X; Ding H; Qin L; Pan Y
    Oncol Lett; 2018 Sep; 16(3):3083-3091. PubMed ID: 30127899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness.
    Peng F; Setyawati MI; Tee JK; Ding X; Wang J; Nga ME; Ho HK; Leong DT
    Nat Nanotechnol; 2019 Mar; 14(3):279-286. PubMed ID: 30692675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.
    Tian L; Goldstein A; Wang H; Ching Lo H; Sun Kim I; Welte T; Sheng K; Dobrolecki LE; Zhang X; Putluri N; Phung TL; Mani SA; Stossi F; Sreekumar A; Mancini MA; Decker WK; Zong C; Lewis MT; Zhang XH
    Nature; 2017 Apr; 544(7649):250-254. PubMed ID: 28371798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
    Panopoulou E; Murphy C; Rasmussen H; Bagli E; Rofstad EK; Fotsis T
    Cancer Res; 2005 Mar; 65(5):1877-86. PubMed ID: 15753386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.